The targeted delivery of a secreted PD-1-blocking scFv by CAR T cells has been proven effective in enhancing anti-tumor efficacy in mouse models of PD-L1+ hematologic and solid tumors in vivo by acting in both a paracrine and autocrine manner [161]. Here, PDCD1 is linked to neoplasm.